Investigator Initiated Research

In addition to sponsoring its own research and research collaborations, Lilly has programs for considering external requests for Lilly provision of study drug and/or financial support for Investigator Initiated Research that is initiated, designed and sponsored by external researchers. Lilly considers such requests for support of Investigator Initiated Research projects based on scientific merit and strategic fit with Lilly’s areas of research interest. These reviews are carried out by global committees comprised of Lilly medical and scientific staff members from relevant therapeutic areas.

This site is intended for Health Care and Research Professionals over the age of 18.

Our Areas of Focus
  • Diabetes
    Lilly Diabetes is committed to address the diverse needs of people with diabetes and consistently support patients as their needs change. We are focused on delivering solutions that will bring simplicity and ease of use in diabetes treatment and information on the effective, safe, timely, and appropriate use of a broad range of therapy in order to improve patient outcomes.
  • Oncology
    Lilly Oncology is dedicated to delivering innovative treatment approaches with the goal of improving the outcomes of people living with cancer. We are driven to accelerate the pace and progress of cancer care by developing a broad portfolio of therapies, including those tailored to unique patients and those that modulate the immune system. Lilly's commitment to improving the length and quality of people's lives is achieved through its internal drug development programs and its support of Investigator Initiated Research. Lilly Oncology focuses its drug development programs in three key areas: cell signaling, tumor microenvironment and immuno-oncology.
  • Headache & Pain
    Since the foundation of the company, Lilly researchers have explored and developed new pain therapies across multiple disease states including headache and chronic pain disorders. The goal of Lilly's research in headache/pain is to provide novel, non-opiate therapeutics that significantly improve the lives of patients living with a range of chronic painful conditions.
  • Immunology
    Lilly Immunology is committed to improving the lives of individuals living with immunological diseases and disorders. We are driven to developing innovative solutions through our broad portfolio of therapeutic agents directed at multiple targets in cytokine pathways. Through internal research programs and support of investigator initiated studies, we are dedicated to long-term partnerships that will enable us to make a real impact on individuals' lives.
  • Neurodegenerative Diseases
    Our goal is to make Alzheimer's dementia preventable by 2025. We will do so with a primary focus in disease modification in Alzheimer's Disease, by selecting therapeutic targets with compelling evidence from human genetics and pathophysiology and using biomarkers to detect pathology and begin treatment earlier in the disease process where there is the greatest opportunity to prevent loss of function. We will complement our disease modification efforts through targeted pursuit of transformative therapies for cognitive / psychiatric symptoms.